CY1109980T1 - Χρηση των ενωσεων ανταγωνιστων toy crth2 στη θεραπεια - Google Patents
Χρηση των ενωσεων ανταγωνιστων toy crth2 στη θεραπειαInfo
- Publication number
- CY1109980T1 CY1109980T1 CY20091101153T CY091101153T CY1109980T1 CY 1109980 T1 CY1109980 T1 CY 1109980T1 CY 20091101153 T CY20091101153 T CY 20091101153T CY 091101153 T CY091101153 T CY 091101153T CY 1109980 T1 CY1109980 T1 CY 1109980T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- cor
- hydrogen
- independently hydrogen
- crth2
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0324763.2A GB0324763D0 (en) | 2003-10-23 | 2003-10-23 | Use of compounds in therapy |
| EP04768943A EP1682121B1 (en) | 2003-10-23 | 2004-10-19 | Use of crth2 antagonist compounds in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109980T1 true CY1109980T1 (el) | 2014-09-10 |
Family
ID=29595698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091101153T CY1109980T1 (el) | 2003-10-23 | 2009-11-06 | Χρηση των ενωσεων ανταγωνιστων toy crth2 στη θεραπεια |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US7582672B2 (enExample) |
| EP (2) | EP2060258A1 (enExample) |
| JP (1) | JP4313819B2 (enExample) |
| KR (1) | KR20060096145A (enExample) |
| CN (1) | CN101141956B (enExample) |
| AT (1) | ATE439129T1 (enExample) |
| AU (1) | AU2004287245B2 (enExample) |
| BR (1) | BRPI0415374B8 (enExample) |
| CA (1) | CA2543199C (enExample) |
| CY (1) | CY1109980T1 (enExample) |
| DE (1) | DE602004022579D1 (enExample) |
| DK (1) | DK1682121T3 (enExample) |
| ES (1) | ES2330113T3 (enExample) |
| GB (1) | GB0324763D0 (enExample) |
| HR (1) | HRP20090577T1 (enExample) |
| IL (1) | IL175085A0 (enExample) |
| NO (1) | NO335228B1 (enExample) |
| NZ (1) | NZ547319A (enExample) |
| PL (1) | PL1682121T3 (enExample) |
| PT (1) | PT1682121E (enExample) |
| RU (1) | RU2412934C2 (enExample) |
| SI (1) | SI1682121T1 (enExample) |
| UA (1) | UA86602C2 (enExample) |
| WO (1) | WO2005044260A1 (enExample) |
| ZA (1) | ZA200603235B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| UY29223A1 (es) | 2004-11-23 | 2006-06-30 | Astrazeneca Ab | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación |
| KR101329903B1 (ko) | 2004-12-27 | 2013-11-14 | 액테리온 파마슈티칼 리미티드 | Ｃｒｔｈ2 수용체 길항제로서의2,3,4,9-테트라하이드로-1ｈ-카르바졸유도체 |
| GB0504150D0 (en) * | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| GB0512944D0 (en) * | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Indolizine compounds |
| WO2007010965A1 (ja) | 2005-07-22 | 2007-01-25 | Shionogi & Co., Ltd. | Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体 |
| EP2397476A3 (en) | 2005-07-22 | 2011-12-28 | Shionogi & Co., Ltd. | Indole derivative having PGD2 receptor antagonist activity |
| GB0518783D0 (en) * | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
| WO2007044309A2 (en) * | 2005-10-05 | 2007-04-19 | Vasix Corporation | Device and method for inhibiting age complex formation |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2007039736A1 (en) | 2005-10-06 | 2007-04-12 | Astrazeneca Ab | Novel compounds |
| ES2380683T3 (es) * | 2005-12-15 | 2012-05-17 | Astrazeneca Ab | Difenil-éteres, -amidas, -sulfuros y - metanos sustituidos para el tratamiento de la enfermedad respiratoria |
| GB0605743D0 (en) * | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
| DK2037967T3 (en) | 2006-06-16 | 2017-03-13 | Univ Pennsylvania | PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI |
| EP2046740B1 (en) | 2006-07-22 | 2012-05-23 | Oxagen Limited | Compounds having crth2 antagonist activity |
| RU2448092C2 (ru) | 2006-08-07 | 2012-04-20 | Актелион Фармасьютиклз Лтд | Производные (3-амино-1,2,3,4-тетрагидро-9н-карбазол-9-ил)уксусной кислоты |
| US20100010034A1 (en) * | 2006-12-21 | 2010-01-14 | George Hynd | Crth2 antagonists |
| EP2136804A1 (en) * | 2007-03-21 | 2009-12-30 | Argenta Oral Therapeutics Limited | Indolizine acetic acid derivatives as crth2 antagonists |
| WO2008118844A1 (en) | 2007-03-23 | 2008-10-02 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibitors |
| JP2010522731A (ja) * | 2007-03-29 | 2010-07-08 | アージェンタ オーラル セラピューティクス リミテッド | Ｃｒｔｈ２受容体リガンドとしてのキノリン誘導体 |
| UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
| WO2009061730A2 (en) | 2007-11-05 | 2009-05-14 | Array Biopharma Inc. | 4-heteroaryl-substituted phenoxyphenylacetic acid |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| DK2327693T3 (da) * | 2007-12-14 | 2012-08-13 | Pulmagen Therapeutics Asthma Ltd | Indoler og terapeutisk anvendelse deraf |
| AU2009204700B2 (en) | 2008-01-18 | 2013-07-04 | Atopix Therapeutics Limited | Compounds having CRTH2 antagonist activity |
| US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| WO2009093026A1 (en) * | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| JP2011509991A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| CA2713139C (en) | 2008-02-01 | 2013-04-23 | Amira Pharmaceuticals, Inc. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
| JP2011512359A (ja) | 2008-02-14 | 2011-04-21 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物 |
| WO2009108720A2 (en) | 2008-02-25 | 2009-09-03 | Amira Pharmaceuticals, Inc. | Antagonists of prostaglandin d2 receptors |
| US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
| EP2300425A4 (en) | 2008-06-24 | 2012-03-21 | Panmira Pharmaceuticals Llc | PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS |
| KR101325367B1 (ko) | 2008-07-03 | 2013-11-11 | 판미라 파마슈티칼스, 엘엘씨 | 프로스타글란딘 ｄ２ 수용체의 길항제 |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039977A2 (en) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
| WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| WO2010085820A2 (en) * | 2009-01-26 | 2010-07-29 | Amira Pharmaceuticals, Inc. | Tricyclic compounds as antagonists of prostaglandin d2 receptors |
| US20120129820A1 (en) * | 2009-02-09 | 2012-05-24 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| KR20120046762A (ko) * | 2009-07-31 | 2012-05-10 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 수용체 길항제의 피부 제형 |
| KR20120038544A (ko) * | 2009-07-31 | 2012-04-23 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 수용체 길항제의 안과용 약학 조성물 |
| US8815917B2 (en) | 2009-08-05 | 2014-08-26 | Panmira Pharmaceuticals, Llc | DP2 antagonist and uses thereof |
| MX2012007927A (es) | 2010-01-06 | 2012-08-15 | Panmira Pharmaceuticals Llc | Antagonistas de dp2 y usos del mismo. |
| JP5291265B2 (ja) | 2010-03-22 | 2013-09-18 | アクテリオン ファーマシューティカルズ リミテッド | ３−（ヘテロアリール−アミノ）−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| US9397745B2 (en) | 2010-05-18 | 2016-07-19 | Qualcomm Incorporated | Hybrid satellite and mesh network system for aircraft and ship internet service |
| US8927559B2 (en) | 2010-10-11 | 2015-01-06 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as CRTH2 antagonists |
| US9469615B2 (en) * | 2010-12-23 | 2016-10-18 | Merck Sharp & Dohme Corp. | Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| PL2697223T3 (pl) | 2011-04-14 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Pochodne kwasu 7-(heteroaryloamino)-6,7,8,9-tetrahydropirydo[1,2-a]indolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny D2 |
| CN103086943B (zh) * | 2011-11-04 | 2015-04-15 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的吲哚类衍生物 |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| CA2859284A1 (en) | 2011-12-16 | 2013-06-20 | Atopix Therapeutics Limited | Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| JP6186933B2 (ja) * | 2013-06-21 | 2017-08-30 | 富士通株式会社 | 接合シート及びその製造方法、並びに放熱機構及びその製造方法 |
| GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| UA117780C2 (uk) | 2014-03-17 | 2018-09-25 | Ідорсія Фармасьютікалз Лтд | Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2 |
| CA2938107A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| TWI695831B (zh) * | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
| EP4420734A3 (en) | 2015-02-13 | 2024-11-06 | Institut National de la Santé et de la Recherche Médicale | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| US11091806B2 (en) | 2015-07-23 | 2021-08-17 | Merck Sharp & Dohme Corp. | Genetic markers associated with response to CRTH2 receptor antagonists |
| AU2016298263A1 (en) | 2015-07-30 | 2018-03-01 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 |
| UA123156C2 (uk) | 2015-09-15 | 2021-02-24 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ |
| US11524958B2 (en) | 2016-07-21 | 2022-12-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tricyclic compound as CRTH2 inhibitor |
| ES2906887T3 (es) * | 2016-07-21 | 2022-04-20 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Derivado del indol usado como inhibidor de CRTH2 |
| CN108101829B (zh) * | 2017-11-19 | 2020-05-12 | 华南理工大学 | 一种吲哚化合物、其制备方法及应用 |
| AU2019209725B2 (en) | 2018-01-19 | 2023-03-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal form of indole derivative and preparation method and use thereof |
| US20220184059A1 (en) | 2018-12-27 | 2022-06-16 | Chiesi Farmaceutici S.P.A. | Process for preparing spherical agglomerates of timapiprant |
| EP4397653A4 (en) * | 2021-09-03 | 2024-12-25 | Shenzhen 01 Life Science and Technology Co., Ltd. | Indole compound, and preparation method therefor and use thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4324418Y1 (enExample) | 1965-04-06 | 1968-10-15 | ||
| US3489767A (en) * | 1966-01-12 | 1970-01-13 | Sumitomo Chemical Co | 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives |
| US3557142A (en) | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
| US3577142A (en) * | 1969-02-28 | 1971-05-04 | Westinghouse Learning Corp | Code translation system |
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| GB1407658A (en) | 1973-03-06 | 1975-09-24 | Ici Ltd | Process for the manufacture of indole derivatives |
| GB1460348A (en) | 1974-02-04 | 1977-01-06 | Ici Ltd | Quinazoline derivativesa |
| DK151884C (da) * | 1979-03-07 | 1988-06-13 | Pfizer | Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf |
| US4363912A (en) * | 1980-12-15 | 1982-12-14 | Pfizer Inc. | Indole thromboxane synthetase inhibitors |
| US4966911A (en) * | 1984-11-20 | 1990-10-30 | Washington Research Foundation | Immunoregulatory agents |
| GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
| US5236945A (en) * | 1990-06-11 | 1993-08-17 | Pfizer Inc. | 1H-indazole-3-acetic acids as aldose reductase inhibitors |
| GB9122590D0 (en) * | 1991-10-24 | 1991-12-04 | Lilly Industries Ltd | Pharmaceutical compounds |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
| JP3228381B2 (ja) * | 1993-10-29 | 2001-11-12 | ソニー株式会社 | Ａｖセレクタ |
| US5641800A (en) | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| IL117208A0 (en) | 1995-02-23 | 1996-06-18 | Nissan Chemical Ind Ltd | Indole type thiazolidines |
| PT837052E (pt) * | 1995-06-21 | 2006-12-29 | Shionogi & Co | Derivados amino bicíclicos e antagonistas de pgd 2 contendo esses derivados |
| DE69734141T2 (de) | 1996-06-05 | 2006-07-13 | Bml Inc. | PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER |
| US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| CN1299347A (zh) | 1998-02-25 | 2001-06-13 | 遗传研究所有限公司 | 磷脂酶抑制剂 |
| ATE269861T1 (de) * | 1998-03-31 | 2004-07-15 | Inst For Pharm Discovery Inc | Substituierte indolalkansäure |
| GB9825524D0 (en) * | 1998-11-20 | 1999-01-13 | Oxford Biomedica Ltd | Vector |
| TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| DE60025368T2 (de) | 1999-08-23 | 2006-09-14 | Bml Inc. | Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren |
| WO2001051489A2 (en) | 2000-01-14 | 2001-07-19 | The Institutes For Pharmaceutical Discovery, Llc | Methods for lowering uric acid levels |
| WO2001051849A1 (en) | 2000-01-14 | 2001-07-19 | Koninklijke Philips Electronics N.V. | Display device |
| WO2001064205A2 (en) | 2000-03-02 | 2001-09-07 | The Institutes For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| JP2001247570A (ja) * | 2000-03-08 | 2001-09-11 | Japan Tobacco Inc | インドール酢酸化合物及びその製造方法 |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| WO2003097042A1 (en) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Pgd2 receptor antagonist |
| EP2423190A1 (en) * | 2002-05-16 | 2012-02-29 | Shionogi&Co., Ltd. | Compounds Exhibiting PGD 2 Receptor Antagonism |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| US7364647B2 (en) | 2002-07-17 | 2008-04-29 | Eksigent Technologies Llc | Laminated flow device |
| ES2268480T3 (es) * | 2002-12-10 | 2007-03-16 | Wyeth | Derivados del acido 3-alquilo- y 3-arilalquilo-1h-indol-1-il-acetico sustituidos como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1). |
| AU2003297398B2 (en) | 2002-12-20 | 2009-09-24 | Amgen Inc. | Asthma and allergic inflammation modulators |
| JP4324418B2 (ja) | 2003-08-05 | 2009-09-02 | 株式会社日立国際電気 | 基板処理装置および半導体デバイスの製造方法 |
| WO2005040114A1 (en) * | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds having crth2 antagonist activity |
| GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| US20090181139A1 (en) * | 2005-04-12 | 2009-07-16 | Mohammed Mehid Farid | Pressure Assisted Thermal Sterilisation or Pasteurisation Method and Apparatus |
| PL65781Y1 (pl) | 2005-08-16 | 2012-02-29 | Katarzyna Kawczyńska | Wkładka kosmetyczna |
| GB0605743D0 (en) | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
| EP2046740B1 (en) | 2006-07-22 | 2012-05-23 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US20110124683A1 (en) | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| AU2009204700B2 (en) | 2008-01-18 | 2013-07-04 | Atopix Therapeutics Limited | Compounds having CRTH2 antagonist activity |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| WO2009093026A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| JP2011509991A (ja) | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
-
2003
- 2003-10-23 GB GBGB0324763.2A patent/GB0324763D0/en not_active Ceased
-
2004
- 2004-10-19 KR KR1020067007822A patent/KR20060096145A/ko not_active Ceased
- 2004-10-19 EP EP09002934A patent/EP2060258A1/en not_active Withdrawn
- 2004-10-19 CN CN2004800311128A patent/CN101141956B/zh not_active Expired - Fee Related
- 2004-10-19 AU AU2004287245A patent/AU2004287245B2/en not_active Ceased
- 2004-10-19 WO PCT/GB2004/004417 patent/WO2005044260A1/en not_active Ceased
- 2004-10-19 HR HR20090577T patent/HRP20090577T1/hr unknown
- 2004-10-19 DK DK04768943T patent/DK1682121T3/da active
- 2004-10-19 SI SI200431276T patent/SI1682121T1/sl unknown
- 2004-10-19 EP EP04768943A patent/EP1682121B1/en not_active Expired - Lifetime
- 2004-10-19 RU RU2006109769/04A patent/RU2412934C2/ru active
- 2004-10-19 ES ES04768943T patent/ES2330113T3/es not_active Expired - Lifetime
- 2004-10-19 NZ NZ547319A patent/NZ547319A/en not_active IP Right Cessation
- 2004-10-19 PT PT04768943T patent/PT1682121E/pt unknown
- 2004-10-19 UA UAA200605567A patent/UA86602C2/ru unknown
- 2004-10-19 AT AT04768943T patent/ATE439129T1/de active
- 2004-10-19 PL PL04768943T patent/PL1682121T3/pl unknown
- 2004-10-19 DE DE602004022579T patent/DE602004022579D1/de not_active Expired - Lifetime
- 2004-10-19 JP JP2006536158A patent/JP4313819B2/ja not_active Expired - Fee Related
- 2004-10-19 CA CA2543199A patent/CA2543199C/en not_active Expired - Fee Related
- 2004-10-19 BR BRPI0415374A patent/BRPI0415374B8/pt not_active IP Right Cessation
- 2004-10-22 US US10/972,060 patent/US7582672B2/en active Active
-
2006
- 2006-03-30 NO NO20061456A patent/NO335228B1/no not_active IP Right Cessation
- 2006-04-20 IL IL175085A patent/IL175085A0/en active IP Right Grant
- 2006-04-21 ZA ZA200603235A patent/ZA200603235B/xx unknown
-
2008
- 2008-09-17 US US12/232,445 patent/US8163936B2/en not_active Expired - Fee Related
- 2008-09-17 US US12/232,447 patent/US8314257B2/en not_active Expired - Fee Related
- 2008-09-17 US US12/232,444 patent/US8163931B2/en not_active Expired - Fee Related
- 2008-09-17 US US12/232,446 patent/US8198314B2/en not_active Expired - Fee Related
-
2009
- 2009-11-06 CY CY20091101153T patent/CY1109980T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109980T1 (el) | Χρηση των ενωσεων ανταγωνιστων toy crth2 στη θεραπεια | |
| EA200800784A1 (ru) | Пиридиновые производные и их применение для лечения психотических расстройств | |
| LUC00155I2 (enExample) | ||
| NO20090216L (no) | Forbindelser med CRTH2 antagonistaktivitet | |
| MX2009002802A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica. | |
| EA201100115A1 (ru) | Новые производные аденина | |
| MX2009011212A (es) | Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica. | |
| EP1697377A4 (en) | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | |
| DK1682138T3 (da) | Heterocykliske inhibitorer af MEK | |
| WO2005028445A3 (en) | Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain | |
| AR038404A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye | |
| AR082075A1 (es) | Derivados de dioxima eter microbicidas | |
| AR001061A1 (es) | Composición fungicida sinergica procedimiento par a combatir hongos nocivos uso de los compuestos que integran dicha composición como componentes sinergicos de la misma | |
| MXPA04000065A (es) | Derivados de aril(o ehteroaril)azolilcarbinoles para el tratamiento de la incontinencia urinaria. | |
| WO2006021655A8 (fr) | Dérivés doxopiperidine, leur préparation et leur application en thérapeutique | |
| TW200716527A (en) | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives | |
| NO20065873L (no) | 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner | |
| AR056447A1 (es) | Un metodo de tratamiento de semillas, una formulacion para el tratamiento de semillas y el uso de arilanidas para tratamiento de semillas | |
| MXPA04012685A (es) | Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina. | |
| ES2132287T3 (es) | Salmicinas, un procedimiento para su preparacion y su uso como producto farmaceutico. | |
| SE0402972D0 (sv) | Novel compounds | |
| WO2008155818A1 (ja) | 頻尿及び尿失禁の予防又は治療剤 |